Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial

Critical Care Medicine

Volumn 25, Issue 7, 1997, Pages 1115-1124

  Opal, Steven M ^a,s   Fisher Jr , Charles J ^b   Dhainaut, Jean François A ^c   Vincent, Jean Louis ^d   Brase, Rainer ^e   Lowry, Stephen F ^f   Sadoff, Jerald C ^g   Slotman, Gus J ^h   Levy, Howard ⁱ   Balk, Robert A ^j   Shelly, Maire P ^k   Pribble, John P ^l   LaBrecque, John F ^l   Lookabaugh, Janice ^l   Donovan, Hugh ^l   Dubin, Howard ^a   Baughman, Robert ^m   Norman, James ⁿ   DeMaria, Eric ^o   Matzel, Klaus ^p   Abraham, Edward ^q   Seneff, Michael ^r   more..

^a BROWN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Université Paris Descartes   (France)

^d ERASME HOSPITAL   (Belgium)

^e Zentralkrankenhaus Links der Weser ^*  (Germany)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h Department of Surgery   (United States)

ⁱ UNIVERSITY OF NEW MEXICO HOSPITAL   (United States)

^j RUSH UNIVERSITY MEDICAL CENTER   (United States)

^k MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^l AMGEN INC   (United States)

^m UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

ⁿ UNIVERSITY OF SOUTH FLORIDA   (United States)

^o VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p Chirurgie Department   (Germany)

^q UNIVERSITY OF COLORADO HOSPITAL   (United States)

^r GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^s BROWN UNIVERSITY   (United States)

more..

Author keywords

Cytokines; Interleukin 1; Interleukin 1 receptor antagonist; Sepsis; Septic shock

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEPSIS; STATISTICAL ANALYSIS;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS;

EID: 0030877935     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199707000-00010     Document Type: Review

References (34)

1. Arend WP: Interleukin-1 receptor antagonist, a new member of the interleukin-1 family. J Clin Invest 1991; 88:1445-1451
2. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77:1627-1652
3. Seckinger P, Williamson K, Balavoine J-F, et al: A urine inhibitor of interleukin-1 activity affects both interleukin-1-alpha and interleukin-1-beta but not tumor necrosis factor. J Immunol 1987; 135:1541-1545
4. Granowitz EV, Clark BD, Mancilla J, et al: Interleukin-1 receptor antagonist competitively inhibits the binding of interleukin-1 to the type II interleukin-1 receptor. J Biol Chem 1991; 266:14147-14150
5. Arend WP, Welgus HG, Thompson RC, et al: Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 1990; 85:1694-1697
6. Eisenberg SP, Evans RP, Arend WP, et al: Primary structure and functional expression of complimentary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343:341-346
7. Hannum CH, Wilcox CJ, Arend WP, et al: Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343:336-340
8. Opal SM: Interleukin-1 receptor antagonist. In: Therapeutic Modulation of Cytokines. Bodmer MW, Henderson B (Eds). Boca Raton, CRC Press, 1996, pp 197-219
9. Aiura K, Gelfand JA, Burke JF, et al: Interleukin-1 receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits. Infect Immun 1993; 61:3342-3345
10. Wakabayashi G, Gelfand JA, Burke JR, et al: A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5:338-343
11. Ohlsson K, Bjork P, Bergenfeldt M, et al: An interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-552
12. Fischer E, Marano MA, Van Zee KJ, et al: Interleukin-1 receptor blockade improves survival in hemodynamic performance in E. coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-1557
13. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of systemic inflammatory response syndrome. JAMA 1993; 269:1829-1835
14. Waaje A, Espevik T: Interleukin-1 potentiates the lethal effects of tumor necrosis factor/cachectin in mice. J Exp Med 1988; 167:1987-1992
15. Granowitz EV, Porat R, Mier JW, et al: Pharmacokinetics, safety, and immunomodutatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 1992; 4:353-360
16. Fisher CJ Jr, Slotman GJ, Opal SM, et al: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-labeled, placebo-controlled multicenter trial. Crit Care Med 1994; 22:12-21
17. Fisher CJ Jr, Dhainaut J-F, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271:1836-1843
18. Knaus WA, Harrell FE, Fisher CJ Jr, et al: The clinical evaluation of new drugs for sepsis: A prospective study design based upon survival analysis. JAMA 1993; 270:1233-1241
19. Fisher CJ Jr, Opal SM, Lowry SF, et al: Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock 1994; 44:1-8
20. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
21. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of a monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. JAMA 1995; 273:934-941
22. Opal SM: Lessons learned from clinical trials of sepsis. J Endotoxin Res 1995; 2:221-226
23. Abraham E, Raffin TA: Sepsis therapy trials: Continued disappointment or reason for hope? JAMA 1994; 271: 1876-1878
24. Sibbald WJ, Vincent J-L: Roundtable conference on clinical trials for the treatment of sepsis. Crit Care Med 1995; 23:394-399
25. Eidelman LA, Sprung CL: Why have new effective therapies for sepsis not been developed? Crit Care Med 1994; 22:1330-1334
26. Cross AS: Anti-endotoxin antibodies: A dead end? Ann Intern Med 1994; 121:58-60
27. Fink MP: Another negative clinical trial for a new agent for the treatment of sepsis: Rethinking the process of developing adjuvant treatments for serious infections. Crit Care Med 1995; 23:989-991
28. Slotman GJ, Quinn JV, Brathwaite CEM, et al: The systemic mediator-associated response test (SMART) predicts organ function in sepsis syndrome. Abstr. Crit Care Med 1996; 24(Suppl) A53
29. Björk L, Andersson J, Ceska M, et al: Endotoxin and Staphylococcus aureus enterotoxin A induce different patterns of cytokines. Cytokine 1992; 4: 513-519
30. Dhainaut J-F, Tenaillon A, LeTulzo Y, et al: Platelet activating factor receptor antagonist BN52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled multicenter trial. Crit Care Med 1994; 22:1720-1728
31. Wenzel RP: Anti-endotoxin monoclonal antibodies - A second look. N Engl J Med 1992; 326:1151-1153
32. Milberg JA, Davis DR, Steinberg KP, et al: Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA 1995; 273:306-309
33. Russel DA, Tucker KK, Khynookoswong N, et al: Combined inhibition of interleukin-1 and tumor necrosis factor in rodent endotoxemia: Improved survival in organ dysfunction. J Infect Dis 1995; 171:1528-1538
34. Cross AS, Opal SM, Palardy JE, et al: The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. J Infect Dis 1993; 167:112-118